GSK-503 is a potent EZH2 inhibitor with potential anticancer activity.
Reference:
1. Cancer Cell. 2013 May 13; 23(5): 677C692.
For research use only. We do not sell to patients.
Name | GSK503 |
---|---|
Iupac Chemical Name | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide |
Synonyms | GSK-503 |
Molecular Formula | C31H38N6O2 |
Molecular Weight | 526.67 |
Smile | O=C(C1=CC(C2=CC=C(N3CCN(C)CC3)N=C2)=CC4=C1C(C)=CN4C(C)C)NCC5=C(C)C=C(C)NC5=O |
InChiKey | HRDQQHUKUIKFHT-UHFFFAOYSA-N |
InChi | InChI=1S/C31H38N6O2/c1-19(2)37-18-21(4)29-25(30(38)33-17-26-20(3)13-22(5)34-31(26)39)14-24(15-27(29)37)23-7-8-28(32-16-23)36-11-9-35(6)10-12-36/h7-8,13-16,18-19H,9-12,17H2,1-6H3,(H,33,38)(H,34,39) |
CAS Number | 1346572-63-1 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | crystalline solid |
---|---|
Purity | 98% |
Storage | 3 years -20ºCpowder |
Solubility | 10 mM in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |